Infliximab treatment maintains employability in patients with early rheumatoid arthritis

Josef S. Smolen, Chenglong Han, Désirée Van Der Heijde, Paul Emery, Joan M. Bathon, Edward Keystone, Joachim R. Kalden, Michael Schiff, Mohan Bala, Daniel Baker, John Han, Ravinder N. Maini, E. William St.Clair

Research output: Contribution to journalArticle

Abstract

Objective. To evaluate the impact of infliximab therapy on the employment status of patients with early rheumatoid arthritis (RA). Methods. Methotrexate (MTX)-naive patients with active early RA were randomly allocated to receive MTX plus placebo or MTX plus infliximab (3 mg/kg or 6 mg/kg) at weeks 0, 2, and 6 and then every 8 weeks through week 46. Data for patients younger than age 65 years were included in the analyses. A patient was categorized as employable if he or she was employed or felt well enough to work if a job were available. Results. The change in actual employment was not significantly different between patients receiving MTX plus infliximab and those receiving MTX plus placebo (0.5% versus 1.3%; P > 0.5). However, the proportion of patients whose status changed from employable at baseline to unemployable at week 54 was smaller in the group receiving MTX plus infliximab compared with that in the group receiving MTX alone (8% versus 14%; P = 0.05). Patients who were treated with infliximab plus MTX had a significantly greater likelihood of improvement rather than deterioration in employability (odds ratio 2.4; P <0.001); this likelihood was not significantly greater in patients receiving MTX alone. The proportion of employed patients who lost workdays during the trial was smaller in the MTX plus infliximab group than in the MTX-alone group (P = 0.010). Conclusion. The actual employment rates among patients in the 2 treatment groups were not different. However, patients with early RA who were treated with MTX plus infliximab had a higher probability of maintaining their employability compared with those who were treated with MTX alone.

Original languageEnglish (US)
Pages (from-to)716-722
Number of pages7
JournalArthritis and Rheumatism
Volume54
Issue number3
DOIs
StatePublished - Mar 2006

Fingerprint

Methotrexate
Rheumatoid Arthritis
Therapeutics
Infliximab
Placebos
Odds Ratio

ASJC Scopus subject areas

  • Immunology
  • Rheumatology

Cite this

Smolen, J. S., Han, C., Van Der Heijde, D., Emery, P., Bathon, J. M., Keystone, E., ... St.Clair, E. W. (2006). Infliximab treatment maintains employability in patients with early rheumatoid arthritis. Arthritis and Rheumatism, 54(3), 716-722. https://doi.org/10.1002/art.21661

Infliximab treatment maintains employability in patients with early rheumatoid arthritis. / Smolen, Josef S.; Han, Chenglong; Van Der Heijde, Désirée; Emery, Paul; Bathon, Joan M.; Keystone, Edward; Kalden, Joachim R.; Schiff, Michael; Bala, Mohan; Baker, Daniel; Han, John; Maini, Ravinder N.; St.Clair, E. William.

In: Arthritis and Rheumatism, Vol. 54, No. 3, 03.2006, p. 716-722.

Research output: Contribution to journalArticle

Smolen, JS, Han, C, Van Der Heijde, D, Emery, P, Bathon, JM, Keystone, E, Kalden, JR, Schiff, M, Bala, M, Baker, D, Han, J, Maini, RN & St.Clair, EW 2006, 'Infliximab treatment maintains employability in patients with early rheumatoid arthritis', Arthritis and Rheumatism, vol. 54, no. 3, pp. 716-722. https://doi.org/10.1002/art.21661
Smolen JS, Han C, Van Der Heijde D, Emery P, Bathon JM, Keystone E et al. Infliximab treatment maintains employability in patients with early rheumatoid arthritis. Arthritis and Rheumatism. 2006 Mar;54(3):716-722. https://doi.org/10.1002/art.21661
Smolen, Josef S. ; Han, Chenglong ; Van Der Heijde, Désirée ; Emery, Paul ; Bathon, Joan M. ; Keystone, Edward ; Kalden, Joachim R. ; Schiff, Michael ; Bala, Mohan ; Baker, Daniel ; Han, John ; Maini, Ravinder N. ; St.Clair, E. William. / Infliximab treatment maintains employability in patients with early rheumatoid arthritis. In: Arthritis and Rheumatism. 2006 ; Vol. 54, No. 3. pp. 716-722.
@article{87e387ea8dc84840b97754f854c600fb,
title = "Infliximab treatment maintains employability in patients with early rheumatoid arthritis",
abstract = "Objective. To evaluate the impact of infliximab therapy on the employment status of patients with early rheumatoid arthritis (RA). Methods. Methotrexate (MTX)-naive patients with active early RA were randomly allocated to receive MTX plus placebo or MTX plus infliximab (3 mg/kg or 6 mg/kg) at weeks 0, 2, and 6 and then every 8 weeks through week 46. Data for patients younger than age 65 years were included in the analyses. A patient was categorized as employable if he or she was employed or felt well enough to work if a job were available. Results. The change in actual employment was not significantly different between patients receiving MTX plus infliximab and those receiving MTX plus placebo (0.5{\%} versus 1.3{\%}; P > 0.5). However, the proportion of patients whose status changed from employable at baseline to unemployable at week 54 was smaller in the group receiving MTX plus infliximab compared with that in the group receiving MTX alone (8{\%} versus 14{\%}; P = 0.05). Patients who were treated with infliximab plus MTX had a significantly greater likelihood of improvement rather than deterioration in employability (odds ratio 2.4; P <0.001); this likelihood was not significantly greater in patients receiving MTX alone. The proportion of employed patients who lost workdays during the trial was smaller in the MTX plus infliximab group than in the MTX-alone group (P = 0.010). Conclusion. The actual employment rates among patients in the 2 treatment groups were not different. However, patients with early RA who were treated with MTX plus infliximab had a higher probability of maintaining their employability compared with those who were treated with MTX alone.",
author = "Smolen, {Josef S.} and Chenglong Han and {Van Der Heijde}, D{\'e}sir{\'e}e and Paul Emery and Bathon, {Joan M.} and Edward Keystone and Kalden, {Joachim R.} and Michael Schiff and Mohan Bala and Daniel Baker and John Han and Maini, {Ravinder N.} and St.Clair, {E. William}",
year = "2006",
month = "3",
doi = "10.1002/art.21661",
language = "English (US)",
volume = "54",
pages = "716--722",
journal = "Arthritis and Rheumatology",
issn = "2326-5191",
publisher = "John Wiley and Sons Ltd",
number = "3",

}

TY - JOUR

T1 - Infliximab treatment maintains employability in patients with early rheumatoid arthritis

AU - Smolen, Josef S.

AU - Han, Chenglong

AU - Van Der Heijde, Désirée

AU - Emery, Paul

AU - Bathon, Joan M.

AU - Keystone, Edward

AU - Kalden, Joachim R.

AU - Schiff, Michael

AU - Bala, Mohan

AU - Baker, Daniel

AU - Han, John

AU - Maini, Ravinder N.

AU - St.Clair, E. William

PY - 2006/3

Y1 - 2006/3

N2 - Objective. To evaluate the impact of infliximab therapy on the employment status of patients with early rheumatoid arthritis (RA). Methods. Methotrexate (MTX)-naive patients with active early RA were randomly allocated to receive MTX plus placebo or MTX plus infliximab (3 mg/kg or 6 mg/kg) at weeks 0, 2, and 6 and then every 8 weeks through week 46. Data for patients younger than age 65 years were included in the analyses. A patient was categorized as employable if he or she was employed or felt well enough to work if a job were available. Results. The change in actual employment was not significantly different between patients receiving MTX plus infliximab and those receiving MTX plus placebo (0.5% versus 1.3%; P > 0.5). However, the proportion of patients whose status changed from employable at baseline to unemployable at week 54 was smaller in the group receiving MTX plus infliximab compared with that in the group receiving MTX alone (8% versus 14%; P = 0.05). Patients who were treated with infliximab plus MTX had a significantly greater likelihood of improvement rather than deterioration in employability (odds ratio 2.4; P <0.001); this likelihood was not significantly greater in patients receiving MTX alone. The proportion of employed patients who lost workdays during the trial was smaller in the MTX plus infliximab group than in the MTX-alone group (P = 0.010). Conclusion. The actual employment rates among patients in the 2 treatment groups were not different. However, patients with early RA who were treated with MTX plus infliximab had a higher probability of maintaining their employability compared with those who were treated with MTX alone.

AB - Objective. To evaluate the impact of infliximab therapy on the employment status of patients with early rheumatoid arthritis (RA). Methods. Methotrexate (MTX)-naive patients with active early RA were randomly allocated to receive MTX plus placebo or MTX plus infliximab (3 mg/kg or 6 mg/kg) at weeks 0, 2, and 6 and then every 8 weeks through week 46. Data for patients younger than age 65 years were included in the analyses. A patient was categorized as employable if he or she was employed or felt well enough to work if a job were available. Results. The change in actual employment was not significantly different between patients receiving MTX plus infliximab and those receiving MTX plus placebo (0.5% versus 1.3%; P > 0.5). However, the proportion of patients whose status changed from employable at baseline to unemployable at week 54 was smaller in the group receiving MTX plus infliximab compared with that in the group receiving MTX alone (8% versus 14%; P = 0.05). Patients who were treated with infliximab plus MTX had a significantly greater likelihood of improvement rather than deterioration in employability (odds ratio 2.4; P <0.001); this likelihood was not significantly greater in patients receiving MTX alone. The proportion of employed patients who lost workdays during the trial was smaller in the MTX plus infliximab group than in the MTX-alone group (P = 0.010). Conclusion. The actual employment rates among patients in the 2 treatment groups were not different. However, patients with early RA who were treated with MTX plus infliximab had a higher probability of maintaining their employability compared with those who were treated with MTX alone.

UR - http://www.scopus.com/inward/record.url?scp=33644929668&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644929668&partnerID=8YFLogxK

U2 - 10.1002/art.21661

DO - 10.1002/art.21661

M3 - Article

VL - 54

SP - 716

EP - 722

JO - Arthritis and Rheumatology

JF - Arthritis and Rheumatology

SN - 2326-5191

IS - 3

ER -